Work

Abstract 817: A prospective, multi-center, phase IV study to evaluate safety and efficacy of Dr. Reddy’s bevacizumab (DRL_BZ) in patients with solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-817

Authors: Narendra Maharaj, Ranjith K, Anand Eswaraiah, Pramod kumar Reddy, Gopichand M, Rajender Singh Arora, Krishna Chaithanya Puligundla, Ashok Kumar Diwan, Tanveer Mohibbhai Maksud

Institutions: Dr. Reddy's Laboratories (India), Healthcare Global Enterprises, MNJ Institute Of Oncology and Regional Cancer Centre, Government Medical College

Language: English

Topic: Biosimilars and Bioanalytical Methods

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409690877

Cites:

Cited by:

Related to: 10